Morphine Pediatric Dose — Analgesia
Morphine is a naturally occurring opioid analgesic that exerts its effect by binding to mu-opioid receptors in the central and peripheral nervous system, producing dose-dependent analgesia and sedation. It is one of the most widely used agents for moderate-to-severe acute pain management in the pediatric population across inpatient, emergency, and perioperative settings. Morphine is available in both parenteral and oral formulations, allowing flexible titration based on clinical need and patient acuity.
Pediatric Dosing
| Route | Dose | Frequency |
|---|---|---|
| IV | 0.05–0.1 mg/kg/dose | Every 2 hours or every 4 hours PRN |
| PO (immediate release) | 0.2–0.5 mg/kg/dose | Every 4 hours or every 6 hours PRN |
Worked example (20 kg child):
IV dose: 20 kg × 0.05–0.1 mg/kg = 1–2 mg IV per dose PRN
PO dose: 20 kg × 0.2–0.5 mg/kg = 4–10 mg PO per dose PRN
Caution in renal failure patients. Morphine’s active metabolite, morphine-6-glucuronide, accumulates in renal impairment and may potentiate respiratory depression and sedation. Consult institutional protocol for dose adjustment guidance in patients with renal insufficiency.
Indications and Clinical Context
Morphine is indicated for the management of moderate-to-severe acute pain in pediatric patients, including pain associated with trauma, surgery, sickle cell vaso-occlusive crisis, burns, and oncologic conditions. It is a first-line parenteral opioid analgesic in many inpatient and emergency department settings and is consistent with established pediatric pain management guidelines. The choice between IV and oral routes is guided by the clinical setting, severity of pain, and the patient’s ability to tolerate enteral medications.
Dosing follows weight-based principles with frequent reassessment of pain scores and sedation levels. The PRN (as-needed) dosing structure outlined here is appropriate for episodic or breakthrough pain; scheduled dosing regimens for persistent pain should be determined in conjunction with institutional pain management protocols.
Administration and Monitoring
For IV administration, morphine should be given as a slow intravenous push over at least 2–5 minutes to reduce the risk of histamine-mediated adverse effects such as pruritus, hypotension, and flushing. The immediate-release oral formulation should be administered with or without food; liquid preparations are preferable for younger children or those unable to swallow tablets. Intraosseous (IO) administration may be used in emergency situations when IV access is unavailable, though consult institutional protocol for IO-specific guidance.
- Monitor: Respiratory rate, oxygen saturation, sedation level, and pain scores at each dose interval
- Adverse effects: Respiratory depression, sedation, nausea, vomiting, pruritus, urinary retention, and constipation
- Renal impairment: Use with caution; metabolite accumulation increases risk of prolonged sedation and respiratory depression
- Reversal agent: Naloxone should be readily available whenever opioids are administered
- Max dose: Not specified in source description — consult institutional protocol for single-dose ceiling limits by age and clinical context
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.